IL1B and inflammatory bowel disease: The inhibitors of ER stress such as TUDCA led to improved symptoms in IBD mouse model, accompanied by reduced levels of interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) in intestine tissues [16].